- Policy
- The Minister's willingness to innovate regulations
- by Lee, Hye-Kyung Feb 20, 2023 05:53am
- Oh Yoo-kyung, head of the Ministry of Food and Drug Safety, met with representatives of pharmaceutical companies and expressed his willingness to innovate regulations. At 2 p.m. today (15th), Director Oh met with representatives of pharmaceutical industries such as Hanmi Pharmaceutical, Dasan Pharmaceutical, Daewoong Pharmaceutical, Amgen
- Policy
- Will there be progress in introducing a checkup for Hep C?
- by Jung, Sae-Im Feb 20, 2023 05:52am
- Attention is focusing on whether the introduction of national screening for hepatitis C, which has been idle for eight years, will be able to make progress this year. At APASL 2023, which was held in Taipei, Taiwan for five days from the 15th, in-depth discussions were held on preparing national policies to combat hepatitis C. The forum examined
- Policy
- Skyrizi benefit will be expanded from next month
- by Lee, Jeong-Hwan Feb 17, 2023 05:50am
- Expanded standards for oral hepatitis B drugs. From March 1, the scope of recognition of drug care benefits by Skyrizi PFS is expected to expand from existing psoriasis to active and progressive psoriatic arthritis. Reva-K and Reba-eye 2% are listed as new benefits, and medical benefits are recognized when administered to "improve corneal epi
- Policy
- NHIS President “will improve the PVA system"
- by Lee, Tak-Sun Feb 17, 2023 05:49am
- Do-Tae Kang, President of the National Health Insurance Service expressed plans to continue managing pharmaceutical expenditures by preparing a plan to improve the price-volume agreement (PVA) negotiation system within the year. Also, Kang added that the NHIS will be applying the refund type of the performance-based risk-sharing agreement
- Policy
- Rebamipide eye drops will be reimb next month
- by Lee, Tak-Sun Feb 16, 2023 05:51am
- Whether the reimbursement of Samil Pharmaceutical and Kukje Pharma’s rebamipide eye drop solutions that were developed as a treatment for dry eye will reorganize the artificial tears market is gaining attention. In particular, with reimbursement reevaluations set to be conducted for hyaluronic acid eye drops that occupy the largest sha
- Policy
- Paxlovid's expiration date has been extended
- by Lee, Hye-Kyung Feb 14, 2023 05:48am
- While the expiration date of Pfizer's COVID-19 treatment Paxlovid has been changed from 12 months to 18 months, experts said that a six-month extension is reasonable for the volume purchased after approval. According to the minutes of the Central Pharmaceutical Review Committee recently released by the Ministry of Food and Drug Safety, th
- Policy
- MFDS prepares a cost-sharing plan
- by Lee, Hye-Kyung Feb 10, 2023 05:53am
- The Ministry of Food and Drug Safety plans to prepare measures to disperse risk responsibility in preparation for the occurrence of drug safety accidents such as unintentional impurity generation and mixed drugs. According to the 4th plan for drug safety management recently released by the Ministry of Food and Drug Safety, related industries suc
- Policy
- MenQuadfi has entered the licensing process
- by Lee, Hye-Kyung Feb 10, 2023 05:53am
- MenQuadfi, Sanofi Pasteur's tetravalent meningococcal vaccine, is expected to be released soon. According to the pharmaceutical industry on the 7th, Sanofi Pasteur completed receiving product licenses from the Ministry of Food and Drug Safety, including clinical trials of MenQuadfi, a vaccine for meningococcal (A, C, Y, W) to prevent invas
- Policy
- Rosuvastatin 2.5mg/Ezetimibe, Hanmi from Daewoong,& Yuhan
- by Lee, Tak-Sun Feb 10, 2023 05:53am
- The combination market, which combines low-dose (2.5 mg) Rosuvastatin + Ezetimibe, is fluctuating with the addition of large pharmaceutical companies. Yuhan Corporation will also join the market, which Hanmi Pharmaceutical first entered at the end of 2021, following Daewoong Pharmaceutical. As the market size is not expected to be small, comp
- Policy
- MOHW opposes legislating premium pricing for KIPC drugs
- by Lee, Jeong-Hwan Feb 10, 2023 05:53am
- The Ministry of Health and Welfare virtually opposed the bill that legislates preferential treatment for drugs manufactured by accredited Korea Innovative Pharmaceutical Companies. The MOHW’s position is that drugs manufactured by Korea Innovative Pharmaceutical Companies already receive preferential treatment, such as premiums provided
